Pfizer: FDA approves migraine nasal spray
(CercleFinance.com) - Pfizer announced on Friday that the US FDA has approved Zavzpret, its nasal spray for the treatment of migraine in adults.
The pharmaceutical company said that a pivotal phase 3 study had established the statistical superiority of Zavzpret over a placebo on the two criteria of absence of pain and disappearance of other troublesome symptoms two hours after the drug was taken.
In some cases in the trial, pain was even relieved within 15 minutes of treatment, Pfizer said in a statement.
Zavzpret belongs to a class of drugs called small molecule calcitonin gene-related peptide (CGRP) receptor antagonists, a new class of products targeting CGRP receptors, which are thought to play a role in pain and migraine.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The pharmaceutical company said that a pivotal phase 3 study had established the statistical superiority of Zavzpret over a placebo on the two criteria of absence of pain and disappearance of other troublesome symptoms two hours after the drug was taken.
In some cases in the trial, pain was even relieved within 15 minutes of treatment, Pfizer said in a statement.
Zavzpret belongs to a class of drugs called small molecule calcitonin gene-related peptide (CGRP) receptor antagonists, a new class of products targeting CGRP receptors, which are thought to play a role in pain and migraine.
Copyright (c) 2023 CercleFinance.com. All rights reserved.